All Stories

  1. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden. The MANTRA-PAF trial

    Article • EP Europace, January 2015, European Society of Cardiology

    Dr Hakan Walfridsson

  2. The cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation: results from a MANTRA-PAF substudy

    Article • EP Europace, October 2014, European Society of Cardiology

    Dr Hakan Walfridsson

  3. Is the acetylcholine-regulated inwardly rectifying potassium current a viable antiarrhythmic target? Translational discrepancies of AZD2927 and A7071 in dogs and humans

    Article • EP Europace, July 2014, European Society of Cardiology

    Dr Leif G Carlsson, Dr Hakan Walfridsson

  4. Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation

    Article • Survey of Anesthesiology, February 2014, Wolters Kluwer Health

    Dr Hakan Walfridsson

  5. The Cost-Effectiveness of Catheter Ablation as First-Line Treatment

    Article • Value in Health, November 2013, Elsevier

    Dr Hakan Walfridsson

  6. Radiofrequency ablation as initial therapy in paroxysmal atrial fibrillation: results on health-related quality of life and symptom burden (The MANTRA-PAF trial)

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Dr Hakan Walfridsson

  7. Cost-effectiveness of radiofrequency catheter ablation as first-line treatment for paroxysmal atrial fibrillation

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Dr Hakan Walfridsson

  8. Catheter ablation versus antiarrhythmic medication as first line therapy in paroxysmal atrial fibrillation: on treatment analysis of the MANTRA-PAF data

    Article • European Heart Journal, August 2013, European Society of Cardiology

    Dr Hakan Walfridsson

  9. Radiofrequency Ablation as Initial Therapy in Paroxysmal Atrial Fibrillation

    Article • New England Journal of Medicine, October 2012, New England Journal of Medicine (NEJM/MMS)

    Dr Hakan Walfridsson

  10. Impact of radiofrequency ablation on health-related quality of life in patients with paroxysmal supraventricular tachycardia compared with a norm population one year after treatment

    Article • Heart & Lung, September 2011, Elsevier

    Dr Hakan Walfridsson

  11. A Randomized Invasive Cardiac Electrophysiology Study of the Combined Ion Channel Blocker AZD1305 in Patients After Catheter Ablation of Atrial Flutter

    Article • Journal of Cardiovascular Pharmacology, September 2010, Wolters Kluwer Health

    Dr Hakan Walfridsson

  12. Effects of AZD0837, a Novel Direct Thrombin Inhibitor, on the Electrophysiological Properties of the Human Heart

    Article • Clinical Drug Investigation, July 2010, Springer Science + Business Media

    Dr Hakan Walfridsson

  13. Activation mapping of focal atrial tachycardia: the impact of the method for estimating activation time

    Article • Journal of Interventional Cardiac Electrophysiology, October 2009, Springer Science + Business Media

    Dr Hakan Walfridsson

  14. Wolff-Parkinson-White Syndrome and Atrioventricular Nodal Re-Entry Tachycardia in a Swedish Population: Consequences on Health-Related Quality of Life

    Article • Pacing and Clinical Electrophysiology, October 2009, Wiley

    Dr Hakan Walfridsson

  15. Cost-effectiveness of Catheter Ablation Treatment for Patients with Symptomatic Atrial Fibrillation

    Article • Journal of Atrial Fibrillation, August 2009, Cardiofront, LLC

    Dr Hakan Walfridsson

  16. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) Trial: clinical rationale, study design, and implementation

    Article • EP Europace, May 2009, European Society of Cardiology

    Dr Hakan Walfridsson

  17. Prophylactic cavotricuspid isthmus block during atrial fibrillation ablation in patients without atrial flutter: a randomised controlled trial

    Article • Heart, March 2009, BMJ

    Dr Hakan Walfridsson

  18. Focal atrial tachycardia: increased electrogram fractionation in the vicinity of the earliest activation site

    Article • EP Europace, October 2008, European Society of Cardiology

    Dr Hakan Walfridsson

  19. Source of inflammatory markers in patients with atrial fibrillation

    Article • EP Europace, May 2008, European Society of Cardiology

    Dr Hakan Walfridsson

  20. Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009

    Article • Heart Rhythm, November 2006, Elsevier

    Dr Hakan Walfridsson

  21. Gender-Related Differences in Patients With Atrioventricular Nodal Reentry Tachycardia

    Article • The American Journal of Cardiology, February 2006, Elsevier

    Dr Hakan Walfridsson

  22. Inflammatory markers in patients with paroxysmal atrial fibrillation

    Article • Heart Rhythm, May 2005, Elsevier

    Dr Hakan Walfridsson

  23. The Impact of Supraventricular Tachycardias on Driving Ability in Patients Referred for Radiofrequency Catheter Ablation

    Article • Pacing and Clinical Electrophysiology, February 2005, Wiley

    Dr Hakan Walfridsson

  24. Perception and Documentation of Arrhythmias after Successful Radiofrequency Catheter Ablation of Accessory Pathways

    Article • Annals of Noninvasive Electrocardiology, July 2001, Wiley

    Dr Nils Edvardsson, Dr Hakan Walfridsson

  25. Sensing of Atrial Fibrillation by a Dual Chamber Pacemaker: How Should Atrial Sensing Be Programmed to Ensure Adequate Mode Shifting?

    Article • Pacing and Clinical Electrophysiology, July 2000, Wiley

    Dr Hakan Walfridsson

  26. Incidence of Sudden Death After Radiofrequency Ablation of the Atrioventricular Junction for Atrial Fibrillation

    Article • The American Journal of Cardiology, November 1997, Elsevier

    Dr Hakan Walfridsson

  27. The Value of Exercise Test, Hotter Monitoring, and Programmed Electrical Stimulation in Detection of Ventricular Arrhythmias in Patients with Hypertrophic Cardiomyopathy

    Article • Pacing and Clinical Electrophysiology, October 1990, Wiley

    Dr Hakan Walfridsson

  28. Tissue oxygen pressure in normal myocardium and across the border zone during coronary artery occlusion in the pig. Effects of different arterial oxygen pressures

    Article • Basic Research in Cardiology, September 1990, Springer Science + Business Media

    Dr Hakan Walfridsson

  29. Myocardial surface oxygen pressure across the border zone in the pig during acute coronary artery occlusion. A comparison of pretreatment with metoprolol or isoprenaline

    Article • Basic Research in Cardiology, September 1987, Springer Science + Business Media

    Dr Hakan Walfridsson

  30. Predictive importance of clinical findings and a predischarge exercise test in patients with suspected unstable coronary artery disease

    Article • The American Journal of Cardiology, February 1987, Elsevier

    Dr Hakan Walfridsson

  31. A multiwire surface oxygen pressure electrode for measurement across zones of normal and damaged tissue

    Article • International journal of clinical monitoring and computing, March 1985, Springer Science + Business Media

    Dr Hakan Walfridsson

  32. Myocardial Oxygen Pressure Across the Lateral Border Zone After Acute Coronary Occlusion in The Pig Heart

    Article • January 1985, Springer Science + Business Media

    Dr Hakan Walfridsson

  33. A multipoint micro antimony pH electrode for tissue surface measurements

    Article • International journal of clinical monitoring and computing, September 1984, Springer Science + Business Media

    Dr Hakan Walfridsson

  34. Skeletal Muscle Surface Oxygen Pressure Fields in Early Myocardial Infarction: A Preliminary Report on the Effects of Nitroglycerine and Oxygen Breathing

    Article • January 1983, Springer Science + Business Media

    Dr Hakan Walfridsson

  35. SKELETAL MUSCLE OXYGEN PRESSURE IN EARLY MYOCARDIAL IN-FARCTION AND THE EFFECTS OF NITROGLYCERINE

    Article • Critical Care Medicine, March 1981, Wolters Kluwer Health

    Dr Hakan Walfridsson